{"id":"NCT01801436","sponsor":"Johnson & Johnson Taiwan Ltd","briefTitle":"A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma","officialTitle":"A Post Approval Commitment Study for Pharmacokinetic Analysis and Providing Expanded Access to Bortezomib (Velcade) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma in Taiwan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2013-02-28","resultsPosted":"2013-05-16","lastUpdate":"2013-05-16"},"enrollment":14,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Bortezomib","otherNames":["VELCADE"]}],"arms":[{"label":"Bortezomib","type":"EXPERIMENTAL"}],"summary":"The purpose of this post marketing study is to determine the plasma concentration of bortezomib (unchanged drug) to assess the pharmacokinetic (PK - the study of the way a drug enters and leaves the blood and tissues over time) properties in the Taiwanese population. It will also provide expanded access (expanded access, sometimes called \"compassionate use,\" is the use of an investigational drug outside of a clinical trial to treat a participant with a serious or immediately life-threatening disease or condition who has no comparable or satisfactory alternative treatment options) to bortezomib for the same group of participants with multiple myeloma (cancer of the types of cells normally found in bone marrow).","primaryOutcome":{"measure":"Number of Participants With Response to Treatment at Day 1 of Cycle 5","timeFrame":"Day 1 of Cycle 5","effectByArm":[{"arm":"Bortezomib","deltaMin":1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":14},"commonTop":["Neutrophil count decreased","White blood cell count decreased","Platelet count decreased","Haemoglobin decreased","Diarrhoea"]}}